Immunoglobulin A (IgA) Nephropathy Therapeutics - Pipeline Analysis, Clinical Trials & Results, Patents, Designations, Collaborations, Patient Size, and Epidemiology Forecast to 2025
NEW YORK, Oct. 30, 2018 (GLOBE NEWSWIRE) -- According to the market research report published by P&S Intelligence, the IgA nephropathy therapeutics pipeline currently exhibits a proliferating trend with 24 drug candidates.
IgA nephropathy, also known as Berger’s disease, is a kidney disorder that occurs when IgA antibody gets settled in the kidneys. It is an auto immune disorder caused due to the accumulation of IgA, which results in inflammation and further damages the glomeruli in kidney. The causes of IgA nephropathy are still not very clear, but it has been stated that the disease occur as an immune response to foreign particles, such as bacteria or virus. This immune response releases IgA antibody, a protein that fight against infections in the body. In certain cases, the disease develops in patients with a family history of IgA nephropathy. Researchers also believe that genetic factors are also a cause of the disease.
Request to get the sample pages: https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis/report-sample
As of March 2018, the IgA nephropathy therapeutics pipeline comprises 24 drug candidates, of which three drug candidates are in Phase III stage of development. The report also provides an overview about the epidemiology of IgA nephropathy in the 7MM (U.S., EU5 [U.K., Germany, France, Italy, and Spain] and Japan), including the number of prevalent, and treated patients in these geographies. Globally, the total number of cases of IgA nephropathy were found to be around 0.45 million in 2017, which is expected to reach 0.6 million by 2025. The U.K., Germany, France, Italy, and Spain are expected to report the largest number of cases of IgA nephropathy, as compared to the U.S. and Japan.
Browse report overview with 58 tables and 26 figures spread through 130 pages and detailed TOC on “IgA Nephropathy Therapeutics - Pipeline Analysis, Clinical Trials & Results, Patents, Designations, Collaborations, Patient Size, and Epidemiology Forecast to 2025” at: https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis
According to the research findings, a majority of the drug candidates for the treatment of IgA nephropathy are being developed to be administered by subcutaneous route. This is mainly due to the several advantages associated with this route of administration, such as sustained release of drug into the body, improved patient’s condition, lower risk of systemic infections, reduced painful administration, improved patient compliance, and less-expensive nature of the drugs.
Make enquiry before placing the order: https://www.psmarketresearch.com/send-enquiry?enquiry-url=iga-nephropathy-pipeline-analysis
Companies are developing drugs with promising targets for the treatment of the disease. These potential targets are expected to possibly stop or slow the progression of the disease with better efficacy and less side effects. For instance, in March 2015, ACTH (Acthar) Gel being developed by Mallinckrodt plc, has shown that treatment with ACTH (Acthar) Gel for at least six months produced a reduction of proteinuria by 30% or more from baseline, ranging from 36.4% to 99.4%, in nearly 80% of the patients enrolled in the trial. ACTH (Acthar) gel reduces intrarenal inflammation by inhibiting nuclear factor kappa B (NF-κB) signaling.
Some of the key players involved in the development of IgA nephropathy therapeutics include Mallinckrodt plc, Calliditas Therapeutics AB, Omeros Corporation, Anthera Pharmaceuticals Inc., Merck KGaA, Rigel Pharmaceuticals Inc., Novartis AG, ChemoCentryx Inc., and Apellis Pharmaceuticals Inc.
More Reports by P&S Intelligence
Acute Kidney Injury Therapeutics Pipeline Analysis
According to the research findings, a majority of the drug candidates for the treatment of AKI are being developed to be administered by the intravenous route. It has been observed that the drugs which are being administered through intravenous route have high efficacy because of their higher bioavailability.
https://www.psmarketresearch.com/market-analysis/acute-kidney-injury-therapeutic-pipeline-analysis
Peanut Allergy Therapeutics Pipeline Analysis
Peanut allergy is one of the most common type of allergies caused by a legume, known as peanut. Peanut is an annual herbaceous plant that belongs to the family of legumes. Other examples of legumes that can cause the disease include lentils, peas, and soybeans. Peanut allergy can be unpredictable and life-threatening and can bring the body into shock (anaphylaxis). The study analyzed that peanut allergy therapeutics pipeline comprises approximately 19 drug candidates in different stages of development.
https://www.psmarketresearch.com/market-analysis/peanut-allergy-therapeutics-pipeline-analysis
About P&S Intelligence
P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.
Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com